ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,631.22
0.28%
Dow Jones
40,211.72
0.53%
US Dollar vs MXN
17.737
0.03%
Brent Oil
83.535
-0.95%
Bitcoin
63,545.51
-2.01%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. CytomX Therapeutics Inc (CTMX)

  7. CytomX Therapeutics Inc (CTMX) Noticias

CTMX

CytomX Therapeutics (CTMX)

CytomX Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CTMX
FechaHoraFuenteTítuloSímboloCompañía
03/02/202007:00GlobeNewswire Inc.CytomX Therapeutics Appoints Alison L. Hannah, M.D. as Chief Medical OfficerNASDAQ:CTMXCytomX Therapeutics Inc
31/01/202009:24Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CTMXCytomX Therapeutics Inc
27/01/202013:04Edgar (US Regulatory)Schedule 13gNASDAQ:CTMXCytomX Therapeutics Inc
17/01/202015:10GlobeNewswire Inc.CytomX Therapeutics Announces New Employment Inducement GrantsNASDAQ:CTMXCytomX Therapeutics Inc
19/12/201907:03GlobeNewswire Inc.CytomX Therapeutics Provides Updates on Lead Clinical Programs and 2020 Portfolio OutlookNASDAQ:CTMXCytomX Therapeutics Inc
16/12/201915:21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CTMXCytomX Therapeutics Inc
11/11/201907:00GlobeNewswire Inc.CytomX Therapeutics to Present at Upcoming Healthcare ConferencesNASDAQ:CTMXCytomX Therapeutics Inc
07/11/201915:14Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CTMXCytomX Therapeutics Inc
07/11/201915:09Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CTMXCytomX Therapeutics Inc
07/11/201915:09GlobeNewswire Inc.CytomX Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
29/10/201915:04GlobeNewswire Inc.CytomX Therapeutics Announces Initiation of Phase 2 Clinical Trial Evaluating the Anti-PD-L1 Probody CX-072 in Combination wi...NASDAQ:CTMXCytomX Therapeutics Inc
24/10/201907:00GlobeNewswire Inc.CytomX Therapeutics to Announce Third Quarter 2019 Financial ResultsNASDAQ:CTMXCytomX Therapeutics Inc
16/10/201917:59Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:CTMXCytomX Therapeutics Inc
14/10/201907:00GlobeNewswire Inc.CytomX Therapeutics Announces Appointment of Amy C. Peterson, M.D. as Chief Development OfficerNASDAQ:CTMXCytomX Therapeutics Inc
07/08/201915:10GlobeNewswire Inc.CytomX Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
06/08/201907:00GlobeNewswire Inc.CytomX Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
30/07/201907:00GlobeNewswire Inc.CytomX Therapeutics to Announce Second Quarter 2019 Financial ResultsNASDAQ:CTMXCytomX Therapeutics Inc
09/07/201910:55Dow Jones NewsCytomX Therapeutics Up 9%; AbbVie Picks Second Target Under CollaborationNASDAQ:CTMXCytomX Therapeutics Inc
09/07/201907:00GlobeNewswire Inc.CytomX Therapeutics Announces Second Target Selection and Program Initiation with AbbVie Under Ongoing, Multi-Program Strate...NASDAQ:CTMXCytomX Therapeutics Inc
21/06/201915:21Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:CTMXCytomX Therapeutics Inc
01/06/201908:00GlobeNewswire Inc.CytomX Therapeutics Provides Update on Anti-PD-L1 Probody CX-072 at 2019 ASCO Annual MeetingNASDAQ:CTMXCytomX Therapeutics Inc
15/05/201916:20GlobeNewswire Inc.CytomX Therapeutics Announces Presentations at 2019 ASCO Annual MeetingNASDAQ:CTMXCytomX Therapeutics Inc
10/05/201911:28Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:CTMXCytomX Therapeutics Inc
09/05/201915:10GlobeNewswire Inc.CytomX Therapeutics Announces First Quarter 2019 Financial ResultsNASDAQ:CTMXCytomX Therapeutics Inc
07/05/201907:00GlobeNewswire Inc.CytomX Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
02/05/201907:00GlobeNewswire Inc.CytomX Therapeutics to Announce First Quarter 2019 Financial ResultsNASDAQ:CTMXCytomX Therapeutics Inc
26/04/201914:56Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:CTMXCytomX Therapeutics Inc
26/04/201914:51Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:CTMXCytomX Therapeutics Inc
22/04/201915:05GlobeNewswire Inc.CytomX Therapeutics Appoints Elaine V. Jones, Ph.D., to Board of DirectorsNASDAQ:CTMXCytomX Therapeutics Inc
10/04/201909:36Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CTMXCytomX Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CTMX

Su Consulta Reciente

NASDAQ
MSFT
Microsoft
NASDAQ
QQQ
Invesco QQQ Trust Series 1
CCOM
SILVER
SILVER
USI
USTECH100
US Tech 100
NYSE
CVX
Chevron
NASDAQ
NVDA
NVIDIA
USOTC
ADDYY
Adidas (QX)
COIN
ETHUSD
Ethereum
FX
USDMXN
US Dollar vs MXN
NYSE
JPM
JP Morgan Chase
COIN
SOLUSD
Solana
NYSE
VZ
Verizon Communications
USOTC
BNPQY
BNP Paribas (QX)
NYSE
MRK
Merck
NYSE
AXP
American Express
NYSE
BAC
Bank of America
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados